# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...
scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the...
FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuti...
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additio...
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, r...
Key highlights of the topline results from the study:SCP-111 demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), ...
scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializin...